NIKKEI 225
38,615.95 -87.56 (-0.23%) HANG SENG
18,524.04 +47.24 (+0.26%) CRUDE OIL
75.51 -0.04 (-0.05%) GOLD FUTURES
2,389.50 -1.40 (-0.06%) DOW
38,886.17 +78.84 (+0.20%) Bitcoin GBP
55,385.73 -238.15 (-0.43%)
GILD Jan 2026 50.000 call
- Zacks
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- Business Wire
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
FOSTER CITY, Calif., June 06, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from the Phase 2b MYR204 open-label study assessing the efficacy and safety of the first-in-class entry inhibitor bulevirtide as monotherapy and in combination with pegylated interferon alfa-2a (PegIFN), in adults living with compensated chronic hepatitis delta virus (HDV) infection. Published in the New England Journal of Medicine (NEJM), the data demonstrate that the investigational combination of bul
- Business Wire
Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
FOSTER CITY, Calif., June 05, 2024--Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary biliary cholangitis (PBC), a rare, chronic inflammatory liver disease. The two-year interim analysis includes people living with PBC who participated in any prior clinical studies of seladelpar (legacy studies) and participants from
